APT Medical Inc
APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China. The company offers electrophysiology products, such as mapping, ablation, and navigated catheter, as well as steerable, and transseptal needle and sheet; and interventional cardiology and peripheral products, including access, diagnostic, therapeutic, and acces… Read more
APT Medical Inc (688617) - Net Assets
Latest net assets as of September 2025: CN¥3.04 Billion CNY
Based on the latest financial reports, APT Medical Inc (688617) has net assets worth CN¥3.04 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.46 Billion) and total liabilities (CN¥423.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.04 Billion |
| % of Total Assets | 87.76% |
| Annual Growth Rate | 42.47% |
| 5-Year Change | 467.63% |
| 10-Year Change | N/A |
| Growth Volatility | 97.63 |
APT Medical Inc - Net Assets Trend (2017–2024)
This chart illustrates how APT Medical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for APT Medical Inc (2017–2024)
The table below shows the annual net assets of APT Medical Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.55 Billion | +30.22% |
| 2023-12-31 | CN¥1.96 Billion | +9.54% |
| 2022-12-31 | CN¥1.79 Billion | +0.00% |
| 2021-12-31 | CN¥1.79 Billion | +297.94% |
| 2020-12-31 | CN¥450.09 Million | +30.12% |
| 2019-12-31 | CN¥345.90 Million | +27.78% |
| 2018-12-31 | CN¥270.70 Million | +26.24% |
| 2017-12-31 | CN¥214.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to APT Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1536.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.64 Billion | 65.02% |
| Common Stock | CN¥97.39 Million | 3.87% |
| Other Comprehensive Income | CN¥87.56 Million | 3.48% |
| Other Components | CN¥695.25 Million | 27.63% |
| Total Equity | CN¥2.52 Billion | 100.00% |
APT Medical Inc Competitors by Market Cap
The table below lists competitors of APT Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
K&S AG
OTCQX:KPLUF
|
$2.42 Billion |
|
Crane NXT Co
NYSE:CXT
|
$2.42 Billion |
|
TBC Bank Group PLC
PINK:TBCCF
|
$2.42 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
$2.42 Billion |
|
Petronet LNG Limited
NSE:PETRONET
|
$2.42 Billion |
|
The Scotts Miracle-Gro Company
F:SCQA
|
$2.41 Billion |
|
Turkiye Sise ve Cam Fabrikalari AS
OTCGREY:TKKYY
|
$2.41 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
$2.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in APT Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,907,142,308 to 2,516,339,545, a change of 609,197,237 (31.9%).
- Net income of 673,151,718 contributed positively to equity growth.
- Dividend payments of 133,970,528 reduced retained earnings.
- Other comprehensive income decreased equity by 24,185,590.
- Other factors increased equity by 94,201,637.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥673.15 Million | +26.75% |
| Dividends Paid | CN¥133.97 Million | -5.32% |
| Other Comprehensive Income | CN¥-24.19 Million | -0.96% |
| Other Changes | CN¥94.20 Million | +3.74% |
| Total Change | CN¥- | 31.94% |
Book Value vs Market Value Analysis
This analysis compares APT Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 54.82x to 9.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥4.29 | CN¥234.95 | x |
| 2018-12-31 | CN¥5.39 | CN¥234.95 | x |
| 2019-12-31 | CN¥5.24 | CN¥234.95 | x |
| 2020-12-31 | CN¥6.90 | CN¥234.95 | x |
| 2021-12-31 | CN¥26.67 | CN¥234.95 | x |
| 2022-12-31 | CN¥26.45 | CN¥234.95 | x |
| 2023-12-31 | CN¥28.43 | CN¥234.95 | x |
| 2024-12-31 | CN¥25.87 | CN¥234.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently APT Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.75%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.59%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.18x
- Recent ROE (26.75%) is above the historical average (19.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 16.10% | 22.51% | 0.61x | 1.18x | CN¥13.06 Million |
| 2018 | 7.97% | 8.90% | 0.74x | 1.21x | CN¥-5.47 Million |
| 2019 | 23.62% | 20.44% | 0.72x | 1.60x | CN¥47.62 Million |
| 2020 | 24.06% | 23.11% | 0.81x | 1.28x | CN¥64.74 Million |
| 2021 | 11.69% | 25.09% | 0.41x | 1.13x | CN¥30.11 Million |
| 2022 | 20.30% | 29.44% | 0.55x | 1.26x | CN¥181.69 Million |
| 2023 | 28.00% | 32.35% | 0.64x | 1.35x | CN¥343.21 Million |
| 2024 | 26.75% | 32.59% | 0.69x | 1.18x | CN¥421.52 Million |
Industry Comparison
This section compares APT Medical Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| APT Medical Inc (688617) | CN¥3.04 Billion | 16.10% | 0.14x | $2.42 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |